• Home
  • Contact us
雀盔肺弊牢 ID PW Forgot ID/PW Register Automatically Log me on

New antiplatelet drugs and novel oral anticoagulant during percutaneous coronary intervention

⒑ NOA have significantly improved the outcomes of patients with NVAfib, but have no current role in ACS patients.
⒑ NOA are likely to present a better safety profile than VKA in patiens undergoing stent implantation, and RCTs are currently addressing this hypothesis.

⒑ Prasugrel and ticagrelor are the standard of care for high risk ACS patients with no increased risk of bleeding.
⒑ Cangrelor could be a useful treatment for reducing intraprocedural complication pending approval and drug cost.

Best Focus


  • lecture
  • case
read more


  • lecture
  • case
read more

百度联盟: 现金赌博网站 赌场 博彩网 百家乐平玩法 北京赛车PK10 足球直播 广东快乐十分开奖 外围赌球 澳门娱乐城 时时彩平台